Quantitative levels of serum CA125 have proven useful to define progression-free survival of serous ovarian cancer patients after they have received first-line therapy [6] and in the management of serous ovarian cancer in patients past their cytoreductive surgery and chemotherapy [7,8,9,10]. This evidence concerns the gene MUC16 and ovarian serous adenocarcinoma.